Show simple item record

Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women

dc.contributor.authorSchwartz, Theresaen_US
dc.contributor.authorStark, Azadehen_US
dc.contributor.authorPang, Judyen_US
dc.contributor.authorAwuah, Baffouren_US
dc.contributor.authorKleer, Celina G.en_US
dc.contributor.authorQuayson, Solomonen_US
dc.contributor.authorKingman, Stephanieen_US
dc.contributor.authorAitpillah, Francisen_US
dc.contributor.authorAbantanga, Francisen_US
dc.contributor.authorJiagge, Evelynen_US
dc.contributor.authorOppong, Joseph K.en_US
dc.contributor.authorOsei‐bonsu, Ernesten_US
dc.contributor.authorMartin, Imanen_US
dc.contributor.authorYan, Xiaoweien_US
dc.contributor.authorToy, Kathyen_US
dc.contributor.authorAdjei, Ernesten_US
dc.contributor.authorWicha, Maxen_US
dc.contributor.authorNewman, Lisa A.en_US
dc.date.accessioned2013-02-12T19:01:17Z
dc.date.available2014-04-02T15:08:08Zen_US
dc.date.issued2013-02-01en_US
dc.identifier.citationSchwartz, Theresa; Stark, Azadeh; Pang, Judy; Awuah, Baffour; Kleer, Celina G.; Quayson, Solomon; Kingman, Stephanie; Aitpillah, Francis; Abantanga, Francis; Jiagge, Evelyn; Oppong, Joseph K.; Osei‐bonsu, Ernest ; Martin, Iman; Yan, Xiaowei; Toy, Kathy; Adjei, Ernest; Wicha, Max; Newman, Lisa A. (2013). "Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women." Cancer 119(3): 488-494. <http://hdl.handle.net/2027.42/96403>en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/96403
dc.description.abstractBACKGROUND: Breast cancers that are negative for the estrogen receptor (ER), the progesterone receptor (PR), and the HER2 (human epidermal growth factor receptor 2) marker are more prevalent among African women, and the biologically aggressive nature of these triple‐negative breast cancers (TNBCs) may be attributed to their mammary stem cell features. Little is known about expression of the mammary stem cell marker aldehyde dehydrogenase 1 (ALDH1) in African women. Novel data are reported regarding ALDH1 expression in benign and cancerous breast tissue of Ghanaian women. METHODS: Formalin‐fixed, paraffin‐embedded specimens were transported from the Komfo Anoyke Teaching Hospital in Kumasi, Ghana to the University of Michigan for centralized histopathology study. Expression of ER, PR, HER2, and ALDH1 was assessed by immunohistochemistry. ALDH1 staining was further characterized by its presence in stromal versus epithelial and/or tumor components of tissue. RESULTS: A total of 173 women contributed to this study: 69 with benign breast conditions, mean age 24 years, and 104 with breast cancer, mean age 49 years. The proportion of benign breast conditions expressing stromal ALDH1 (n = 40, 58%) was significantly higher than those with cancer (n = 44, 42.3%) ( P = .043). Among the cancers, TNBC had the highest prevalence of ALDH1 expression, either in stroma or in epithelial cells. More than 2‐fold higher likelihood of ALDH1 expression was observed in TNBC cases compared with other breast cancer subtypes (odds ratio = 2.38, 95% confidence interval 1.03‐5.52, P = .042). CONCLUSIONS: ALDH1 expression was higher in stromal components of benign compared with cancerous lesions. Of the ER‐, PR‐, and HER2‐defined subtypes of breast cancer, expression of ALDH1 was highest in TNBC. Cancer 2013. © 2012 American Cancer Society. Mammary stem cells, as identified by cells expressing the marker aldehyde dehydrogenase 1 (ALDH1), appear to be correlated with malignant transformation and progression of breast tissue into biologically aggressive phenotypes. This study reveals increased expression of ALDH1 in benign and malignant tissue of women from the western sub‐Saharan African nation of Ghana, a population known to have higher frequency of triple‐negative breast cancer, and ALDH1 expression in the malignant specimens was found to be associated with risk of triple‐negative breast cancer.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherAldehyde Dehydrogenase 1en_US
dc.subject.otherTriple‐Negative Breast Canceren_US
dc.subject.otherAfrican Ancestryen_US
dc.subject.otherBreast Canceren_US
dc.subject.otherStem Cell Markeren_US
dc.titleExpression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian womenen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumBreast Care Center, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, 3308 Cancer Center, Ann Arbor, MI 48109‐0932en_US
dc.contributor.affiliationumDepartment of Pathology, School of Medicine, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumBreast Care Center, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumComprehensive Cancer Center, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Surgery, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherUniversity of Illinois at Chicago, School of Public Health, Chicago, Illinoisen_US
dc.contributor.affiliationotherCenter for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvaniaen_US
dc.contributor.affiliationotherCenter for Health Research, Geisinger Health System, Danville, Pennsylvaniaen_US
dc.contributor.affiliationotherDepartment of Pathology and Laboratory Medicine, Henry Ford Health System, Detroit, Michiganen_US
dc.contributor.affiliationotherKomfo Anoyke Teaching Hospital, Kumasi, Ghanaen_US
dc.identifier.pmid22930220en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/96403/1/27737_ftp.pdf
dc.identifier.doi10.1002/cncr.27737en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceMatsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332 ‐ 2336.en_US
dc.identifier.citedreferenceStark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence of triple‐negative breast cancer: findings from an international study. Cancer 2010; 116: 4926 ‐ 4932.en_US
dc.identifier.citedreferenceHuo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over‐representation of triple‐negative breast cancer. J Clin Oncol 2009; 27: 4515 ‐ 4521.en_US
dc.identifier.citedreferenceFregene A, Newman LA. Breast cancer in sub‐Saharan Africa: how does it relate to breast cancer in African‐American women? Cancer 2005; 103: 1540 ‐ 1550.en_US
dc.identifier.citedreferenceCarey L, Winer E, Viale G, Cameron D, Gianni L. Triple‐negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683 ‐ 692.en_US
dc.identifier.citedreferenceAnders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple‐negative breast cancer. Clin Breast Cancer 2009; 9 Suppl 2: S73 ‐ 81.en_US
dc.identifier.citedreferenceGinestier C, Wicha MS. Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res 2007; 9: 109.en_US
dc.identifier.citedreferenceHarmes DC, DiRenzo J. Cellular quiescence in mammary stem cells and breast tumor stem cells: got testable hypotheses? J Mammary Gland Biol Neoplasia 2009; 14: 19 ‐ 27.en_US
dc.identifier.citedreferenceKunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, and Keeler CG. EZH2 and ALDH‐1 mark breast epithelium at risk for breast cancer development. Modern Pathology 2011; 24: 786 ‐ 793.en_US
dc.identifier.citedreferenceGinestier C, Hur MH, Charafe‐Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555 ‐ 567.en_US
dc.identifier.citedreferenceNalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal‐like markers and features of aggressive tumours in African breast cancer. Br J Cancer 2010; 102: 369 ‐ 375.en_US
dc.identifier.citedreferenceAmerican Cancer Society. Breast Cancer Facts & Figures 2009‐2010. Atlanta, GA: American Cancer Society, Inc.en_US
dc.identifier.citedreferenceSEER Cancer Statistics Review, 1975‐2006, based on November 2008 SEER data submission, posted to the SEER web site, 2009 at http://seer.cancer.gov/csr/1975_2006/. National Cancer Institute. Accessed October 1, 2011.en_US
dc.identifier.citedreferenceParise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol 2010; 76: 44 ‐ 52.en_US
dc.identifier.citedreferenceCarey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492 ‐ 2502.en_US
dc.identifier.citedreferenceAmirikia KC, Mills P, Bush J, Newman LA. Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American women: Implications for breast cancer screening recommendations. Cancer 2011; 117: 2747 ‐ 2753.en_US
dc.identifier.citedreferencehttp://www.ghanaweb.com/GhanahomePage/NewsArchive/artikle.php?ID=180999. Accessed August 25, 2011.en_US
dc.identifier.citedreferenceSegal R. The Black Diaspora: Five Centuries of the Black Experience Outside Africa. Gordonsvillle, VA: Farrar Straus and Giroux Publishing Company, 1995.en_US
dc.identifier.citedreferenceBird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 2008; 15: 1983 ‐ 1988.en_US
dc.identifier.citedreferenceWicha MS, Liu S, Dontu G. Cancer stem cells: an old idea‐‐a paradigm shift. Cancer Res 2006; 66: 1883 ‐ 1890; discussion 95 ‐ 96.en_US
dc.identifier.citedreferenceCollins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946 ‐ 10951.en_US
dc.identifier.citedreferenceFang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328 ‐ 9337.en_US
dc.identifier.citedreferenceLi C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030 ‐ 1037.en_US
dc.identifier.citedreferenceO'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106 ‐ 110.en_US
dc.identifier.citedreferencePrince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973 ‐ 978.en_US
dc.identifier.citedreferenceRicci‐Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon‐cancer‐initiating cells. Nature 2007; 445: 111 ‐ 115.en_US
dc.identifier.citedreferenceSingh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396 ‐ 401.en_US
dc.identifier.citedreferenceAl‐Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004; 14: 43 ‐ 47.en_US
dc.identifier.citedreferenceAl‐Hajj M, Wicha MS, Benito‐Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983 ‐ 3988.en_US
dc.identifier.citedreferenceDontu G, Al‐Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36 Suppl 1: 59 ‐ 72.en_US
dc.identifier.citedreferenceRusso JE, Hilton J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res 1988; 48: 2963 ‐ 2968.en_US
dc.identifier.citedreferenceZhou L, Jiang Y, Yan T, et al. The prognostic role of cancer stem cells in breast cancer: a meta‐analysis of published literatures. Breast Cancer Res Treat 2010; 122: 795 ‐ 801.en_US
dc.identifier.citedreferenceNeumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010; 176: 2131 ‐ 2138.en_US
dc.identifier.citedreferencePark SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell‐related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16: 876 ‐ 887.en_US
dc.identifier.citedreferenceCharafe‐Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1‐positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45 ‐ 55.en_US
dc.identifier.citedreferenceYoshioka T, Umekita Y, Ohi Y, et al. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node‐positive breast cancers: a long‐term follow‐up study. Histopathology 2011; 58: 608 ‐ 616.en_US
dc.identifier.citedreferenceResetkova E, Reis‐Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010; 123: 97 ‐ 108.en_US
dc.identifier.citedreferenceHeerma van Voss MR, van der Groep P, Bart J, van der Wall E, van Diest PJ. Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol (Dordr) 2011; 34: 3 ‐ 10.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.